Related Experiment Video

Updated: Jun 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

[The coagulation factor VII gene polymorphisms in patients with myocardial infarction in Ningxia Hui and Han

Hui Huang1, Shaobin Jia, Shulan Chen

  • 1Center of Cardiology, the Affiliated Hospital of Ningxia Medical College, Yinchuan, Ningxia, 750004 PR China.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics
|December 3, 2009
PubMed

Insights

Genetic variations in coagulation factor VII (F VII) are linked to coronary heart disease (CHD) and myocardial infarction risk. Specific F VII gene polymorphisms, like R353Q and -323 0/10 bp, show protective effects in certain populations.

Area of Science:

  • Cardiovascular Genetics
  • Hematology
  • Population Genetics

Background:

  • Coronary heart disease (CHD) and myocardial infarction (MI) are significant health concerns.
  • Coagulation factor VII (F VII) plays a crucial role in the blood clotting cascade.
  • Genetic variations in the F VII gene may influence susceptibility to cardiovascular diseases.

Purpose of the Study:

  • To investigate activated coagulation factor VII (F VIIa) levels and specific F VII gene polymorphisms (R353Q, -323 0/10 bp, HVR4) in patients with CHD and MI.
  • To compare these characteristics between Ningxia Hui and Han populations.

Main Methods:

  • Plasma F VIIa levels were measured using the recombinant tissue factor method.
  • F VII gene polymorphisms (R353Q, -323 0/10 bp, HVR4) were identified by polymerase chain reaction (PCR).
  • Study included angiographically proven CHD patients and healthy controls from Hui and Han populations.

Main Results:

  • Plasma F VIIa levels were significantly higher in CHD and MI patients compared to controls in both populations.
  • Significant differences in R353Q and -323 0/10 bp genotype and allele frequencies were observed between disease groups and in relation to MI in the Hui and Han populations.
  • Individuals with the RR genotype had higher F VIIa levels than Q allele carriers in the Hui population.

Conclusions:

  • Polymorphisms in the F VII gene (R353Q, -323 0/10 bp, HVR4) exist in Hui and Han populations.
  • The Q allele of F VII gene R353Q may offer protection against MI in the Hui population.
  • The 10 allele of the -323 0/10 bp locus may be protective against MI in both Hui and Han populations, and F VIIa levels are influenced by F VII gene R353Q polymorphism.
Abstract

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...